We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
The year has barely begun, but legislators in several states have already introduced anti-compounding bills pushed by Eli Lilly or Novo Nordisk.
They're a critical — and much-appreciated — part of everything we do!
If you’re coming to APC’s 2026 Owner Summit in Austin, why not come a day early? We’ve got two reasons for ya!
Our new “Snapshot of Pharmacy Compounding in America” paints the clearest picture available of the compounding profession today.
Novo Nordisk is still pushing to have semaglutide added to the Demonstrably Difficult to Compound List.
.png?width=410&height=320&name=image-container%20(1).png)
.png?width=410&height=320&name=image-container%20(2).png)
.png?width=411&height=320&name=image-container%20(3).png)
.png?width=410&height=320&name=image-container%20(4).png)
.png)
.png?width=17&height=16&name=folder%20(1).png){kind=small}
%20Pharma-GS.png)
